Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

More Coffee, Less Cirrhosis, Study Says

February 2, 2016 8:06 am | by Seth Augenstein, Digital Reporter | News | Comments

Coffee, subject to a tug-of-war in positive and negative health studies, has its latest supporting claim: that it helps prevent liver cirrhosis. The meta-analysis of coffee’s effects found much less cirrhosis in drinkers of extra coffee, according to the study in the journal Alimentary Pharmacology and Therapeutics, a Wiley publication. Read more...

TOPICS:

WHO Declares ZIKA Virus a Global Health Emergency

February 2, 2016 8:06 am | by Stephanie Guzowski, Editor | News | Comments

The World Health Organization (WHO) on Monday officially declared the Zika virus a global health emergency, and will be mobilizing funds for research and escalating efforts to fight the virus, which is “spreading explosively” in the Americas. Read more...

TOPICS:

The Cell that Caused Melanoma

February 1, 2016 11:11 am | by Harvard University | News | Comments

A team led by Harvard Medical School researchers at Boston Children’s Hospital has, for the first time, visualized the origins of cancer from the first affected cell and watched its spread in a live animal. Read more...

TOPICS:
Advertisement

Basic Science Disappearing From Medical Journals, Study Finds

February 1, 2016 11:02 am | News | Comments

A new study has found a steep decline in the number of scholarly papers about basic science published in leading medical journals in the last 20 years. "This rapid decline in basic science publications is likely to affect physicians' understanding of and interest in the basic mechanisms of disease and treatments," said lead author of the study. Read more...

TOPICS:

Walgreens Suspends Theranos California Lab After U.S. Report

February 1, 2016 10:48 am | by Bloomberg News | News | Comments

Walgreens Boots Alliance Inc. said it will stop sending lab tests to Theranos Inc.’s Newark, California, facility after U.S. regulators found severe deficiencies at the lab. Read more...

TOPICS:

Gilead CEO Martin to Step Down, Will Be Replaced by COO

February 1, 2016 10:27 am | by Bloomberg News | News | Comments

Gilead Sciences Inc. Chief Executive Officer John Martin, under whom the company developed one of the fastest-selling drugs of all time, will step down and be replaced by Chief Operating Officer John Milligan. Read more..

TOPICS:

Drug Discovery for Rare Diseases

February 1, 2016 10:15 am | by Samuel Falsetti, PhD, Partner, Director of Clinical Strategy, Cambridge BioMarketing | Articles | Comments

Q&A on the challenges, approaches and best practices for discovering drugs for the rare disease market. Read more...

TOPICS:

Hard-hitting Antibiotics May Not Prevent Evolution of Drug Resistance

February 1, 2016 10:14 am | by Penn State University | News | Comments

The standard practice of treating infections with the highest tolerable dose of antibiotic medications may not always be best way of preventing the evolution of drug resistance, a new study suggests. Read more...

TOPICS:
Advertisement

Zika Not Likely to Affect Large Parts of U.S., Medical Geographer Says

February 1, 2016 9:42 am | by University at Buffalo | News | Comments

There's no reason to suspect Zika will be much different from dengue fever, and those outbreaks in the United States have been pretty locally contained, according to Jared Aldstadt, University at Buffalo associate professor of geography in the College of Arts and Sciences. Read more...

TOPICS:

Brains with Schizophrenia Vary Depending on Type of Schizophrenia

February 1, 2016 9:37 am | by University of Grenada | News | Comments

An international team, made up of researchers from the University of Granada, Washington University in St. Louis, and the University of South Florida, has linked the symptoms of schizophrenia with the anatomical characteristics of the brain, by employing magnetic resonance imaging (MRI). Read more...

TOPICS:

Britain Approves Controversial Gene-editing Technique

February 1, 2016 9:27 am | by Maria Cheng, AP Medical Writer | News | Comments

Britain's fertility regulator has approved a scientist's request to edit the human genetic code in an effort to fight inherited diseases - but critics fear the new technique crosses too many ethical boundaries. Read more...

TOPICS:

New Biomarker to Assess Stem Cells Developed

February 1, 2016 9:18 am | by University College London | News | Comments

A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). Read more...

TOPICS:

Life at Zika Epicenter a Struggle for Afflicted Family

February 1, 2016 9:17 am | by Mauricio Savarese and Jenny Barchfield, Associated Press | News | Comments

Around the fifth month of her pregnancy, Daniele Ferreira dos Santos fell ill with a high fever and angry red splotches on her skin. Read more....

TOPICS:

Multiple Sclerosis Drug Tied to Rising JC Virus Antibody Levels

January 29, 2016 10:16 am | by American Academy of Neurology | News | Comments

People who take the drug natalizumab for multiple sclerosis may have up to a 10 times greater risk of developing a risk biomarker for activity of a virus that can lead to an often fatal brain disease, according to a study published in the January 27, 2016, online issue of Neurology Neuroimmunology and Neuroinflammation, a medical journal of the American Academy of Neurology. Read more...

TOPICS:

Tresiba: Lower Rate of Hypoglycemia Than Insulin Glargine In Phase 3b Trial

January 29, 2016 10:12 am | News | Comments

Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomized, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine. The overall purpose of the trial was to compare the hypoglycemia occurrence in people with type 2 diabetes treated with Tresiba or insulin glargine.  Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading